Rademikibart Achieves 'Best-In-Class' Potential in Pivotal Phase 3 Atopic Dermatitis Study
CNTB has more than doubled off its 52-week low of $0.51 on elevated volume (2.8× avg).
Summary
Connect Biopharma announced highly positive Phase 3 results for its drug candidate, Rademikibart, in the treatment of atopic dermatitis. The study demonstrated "best-in-class potential" with rapid and durable efficacy over 52 weeks, alongside a favorable safety profile comparable to placebo. This pivotal data significantly de-risks the asset and represents a major value inflection point for the company, especially given its small market capitalization. The strong efficacy and safety profile could position Rademikibart favorably in a competitive market. Investors will now look for details on regulatory submission timelines and potential partnership or commercialization strategies.
At the time of this announcement, CNTB was trading at $3.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $192.9M. The 52-week trading range was $0.51 to $3.82. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.